Dexcom vs Idexx Laboratories
Dexcom reported revenue of $4.7 billion in fiscal 2025, about the same as Idexx Laboratories' $4.3 billion in fiscal 2025. Dexcom's revenue grew 15.6% in its latest year, and Idexx Laboratories' grew 10.4%. Dexcom had an operating margin of 19.6%, against 31.6% at Idexx Laboratories. Free cash flow was $1.1 billion at Dexcom and $1.1 billion at Idexx Laboratories.
Side by side
| Dexcom | Idexx Laboratories | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4.7B | $4.3B |
| Revenue growth | 15.6% | 10.4% |
| Revenue growth a year, last 5 years | 19.3% | 9.7% |
| Gross margin | 60.1% | 61.8% |
| Operating margin | 19.6% | 31.6% |
| Net margin | 17.9% | 24.6% |
| Free cash flow | $1.1B | $1.1B |
| Free cash flow margin | 23.1% | 24.6% |
| Return on capital | 44.9% | 57.3% |
| Net debt to EBITDA | −0.6x | 0.2x |
| Dividends and buybacks | $500M | $1.2B |
| Change in diluted share count | −1.7% | −2.7% |
| Last close | $78.57 | $570.21 |
| P/E at the last close | 31.2× | 40.1× |
| Insider trades, last 12 months | bought $1.0 million, sold $12.8 million | sold $37.7 million |
| Piotroski F-score | 8 of 9 | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
DexcomIdexx Laboratories
Operating margin
Percent of revenue
DexcomIdexx Laboratories
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
DexcomIdexx Laboratories
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Dexcom and Idexx Laboratories pages.